The EU Medical Device Regulation (MDR) is the framework a device must satisfy before it can carry a CE mark and be sold anywhere in the European Union. For a US company already working toward FDA clearance, the short version is this: Europe is a second, largely independent compliance project. You will need a classification under EU rules, a full technical documentation file, a quality management system, clinical evidence, a notified body assessment for anything above the lowest risk class, an EU authorized representative, a UDI and EUDAMED registration, and a post-market surveillance system. MDR is more demanding than the directive it replaced, and clinical evidence expectations are the biggest single change.

Projects House is an engineering firm, not a regulatory consultancy. This article is educational only and is not regulatory advice; engage qualified European regulatory support for your actual submission.

No MDR, no European market

There is no partial entry and no grandfathering worth planning around. Without a valid CE mark under MDR, a device cannot lawfully be placed on the EU market, regardless of how many other jurisdictions have cleared it. FDA clearance carries no weight with a notified body, and CE marking carries no weight with the FDA. Some technical evidence is reusable — electrical safety, biocompatibility, software documentation, risk management — but the submissions themselves are separate.

A structural difference worth internalizing: the FDA is a government agency that reviews submissions directly. In Europe, the manufacturer declares conformity, and a notified body — a commercial organization designated by an EU member state — audits the manufacturer's quality system and assesses the technical documentation. You are hiring and being audited, not applying and waiting. If you are used to the FDA approval process for medical devices, this reversal takes some adjustment.

Step one: classification

MDR sorts devices into Class I, IIa, IIb, and III using a set of classification rules based on invasiveness, duration of contact, whether the device is active, and its intended purpose. The class determines the conformity assessment route and therefore most of the cost and timeline.

  • Class I (non-sterile, non-measuring, non-reusable-surgical) — the manufacturer can self-declare, without notified body involvement in the assessment.
  • Class I sterile, measuring, or reusable surgical — notified body involvement limited to specific aspects.
  • Class IIa and IIb — notified body assessment of the quality system plus technical documentation sampling or review.
  • Class III and implantables — full assessment of the design dossier, with the heaviest clinical evidence expectations.

EU classes do not map cleanly onto US ones. A device that is Class II in the US can land in IIa, IIb, or even III in Europe, and software is classified more aggressively under MDR than many teams expect. Compare against the US framework in FDA medical device classes rather than assuming equivalence, and if your product is software-driven read software as a medical device alongside it.

What MDR actually requires

  • General safety and performance requirements. A checklist of essential requirements, each addressed with a stated method and specific evidence. This is the backbone of the file.
  • A quality management system, in practice built to ISO 13485. The notified body audits it and returns periodically.
  • Risk management across the full lifecycle, structured to ISO 14971, with benefit-risk conclusions that the clinical evaluation supports.
  • Technical documentation covering design, manufacturing, verification and validation, labeling, and instructions for use in the required languages of every market you sell into.
  • Clinical evaluation. A structured argument from clinical data. Relying on published literature about someone else's device (the old "equivalence" route) is far harder under MDR, and for higher-class and implantable devices a clinical investigation is often unavoidable. This is the single most common reason a European program takes longer than planned.
  • Harmonized standards testing as applicable — electrical safety and EMC for active devices under the IEC 60601 family, biological safety under ISO 10993, usability, sterility, and software lifecycle standards.
  • Post-market surveillance and vigilance. A PMS plan, periodic safety update reports for higher classes, trend reporting, and post-market clinical follow-up. Compliance does not end at launch — it becomes an operating obligation.
  • UDI and EUDAMED. Unique device identification on labeling and registration in the European database.

Notified bodies and the EU authorized representative

Two organizational realities catch US companies off guard.

First, notified body capacity is limited. Designation under MDR is demanding and the number of designated bodies is smaller than the demand, so queues are real and you should approach candidates early. Also check the designation scope: a notified body is only designated for particular device categories, so not every body can assess your product.

Second, a manufacturer outside the EU must appoint an EU authorized representative established within the Union. The authorized representative is named on the labeling, holds a mandate, keeps documentation available to authorities, and carries legal responsibilities. It is not a mailbox service — the relationship is contractual and consequential, and its obligations should be understood before signing. You will also need to think about importers and distributors, each of which has defined duties under MDR.

Cost and timeline

Honest ranges only, because class dominates everything. A genuine self-declared Class I device with no notified body assessment can be a modest project, mostly documentation effort, in the low tens of thousands of dollars. A Class IIa or IIb device with notified body fees, testing to harmonized standards, and a clinical evaluation built on existing data typically runs into the low-to-mid six figures once internal effort is counted. A Class III or implantable device requiring its own clinical investigation is a multi-million-dollar program with a multi-year clock. Recurring costs continue after approval: annual notified body surveillance audits, PMS reporting, and periodic recertification.

Timelines are governed less by the work than by two queues — notified body availability and clinical data collection. Plan on many months at minimum even for a straightforward IIa device, and years for anything needing a clinical investigation. Fold these figures into your overall medical device development cost planning rather than treating Europe as an afterthought.

What this means for a startup deciding where to launch

Three practical conclusions. One: choose your first market deliberately and build the evidence package for it, rather than trying to satisfy both regulators simultaneously with an underfunded program. Two: design the evidence in from the beginning — a design history file, risk file, and usability record built during development serve both jurisdictions, whereas reconstructing them later serves neither. Three: budget the clinical question first. Under MDR, clinical evidence is the schedule driver, and the earliest useful action is an honest assessment of whether existing data can carry your claim or whether you need your own study.

Common mistakes worth naming: assuming FDA clearance shortens the European path; assuming your US classification carries over; writing broad marketing claims that the clinical evidence cannot support; leaving translation and labeling to the end; and treating post-market surveillance as paperwork instead of a staffed process.

Projects House develops medical devices with the regulatory endgame designed in from the first sketch, generating verification evidence and documentation as the engineering happens, alongside your regulatory advisors on both sides of the Atlantic. Describe your device through our contact form to discuss the pathway.